Cowen Downgrades Threshold Pharmaceuticals (THLD) to Market Perform

Cowen downgraded Threshold Pharmaceuticals (NASDAQ: THLD) from Outperform to Market Perform.

Analyst Eric Schmidt commented, "Threshold and partner Merck KGaA announced that neither of evofosfamide's pivotal trials in pancreatic cancer or sarcoma met its primary OS endpoint. The results are disappointing, and likely to reduce optimism for THLD's only other clinical asset, a second hypoxia activated prodrug in Phase II development (tarloxotinib targeting EGFR). We are downgrading shares from Outperform to Market Perform."

For an analyst ratings summary and ratings history on Threshold Pharmaceuticals click here. For more ratings news on Threshold Pharmaceuticals click here.

Shares of Threshold Pharmaceuticals closed at $3.34 yesterday.

You May Also Be Interested In

• Morgan Stanley Double Downgrades AU Optronics (2409:TT) (AUO) to Underweight
• JPMorgan Downgrades Five Below (FIVE) to Neutral
• Domino's Pizza (DPZ) PT Raised to $475 at Wells Fargo